Oxyquinoline

Oxyquinoline

SCHEMBL5166153

N#Cc1ccc(B(O)c2cccc(F)c2)cc1.Oc1cccc2cccnc12

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 1/20 0.47
CHRM1 P11229 1/20 0.47
TSHR P16473 1/20 0.47
COMT P21964 1/20 0.47
ADRA1A P35348 1/20 0.47
METAP2 P50579 1/20 0.47
METAP1 P53582 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
KDM4E B2RXH2 4/20 0.42
ALOX12 P18054 2/20 0.42
PKM P14618 1/20 0.41
EGLN1 Q9GZT9 2/20 0.39
GLO1 Q04760 2/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
PDE4A P27815 1/20 0.37
PDE4B Q07343 1/20 0.37
PDE4C Q08493 1/20 0.37
PDE4D Q08499 1/20 0.37
SLC40A1 Q9NP59 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Oxyquinoline SCHEMBL5167257 0.92 MMP2 (0.48) MMP2CHRM1TSHRCOMTADRA1A
Oxyquinoline SCHEMBL5163996 0.87 MMP2 (0.47) MMP2CHRM1TSHRCOMTADRA1A
Oxyquinoline SCHEMBL5167712 0.86 MMP2 (0.44) MMP2CHRM1TSHRCOMTADRA1A
Oxyquinoline SCHEMBL5165569 0.82 METAP2 (0.49) MMP2CHRM1TSHRCOMTADRA1A
Oxyquinoline SCHEMBL5166047 0.82 METAP2 (0.44) MMP2CHRM1TSHRCOMTADRA1A
SCHEMBL1138626 0.82 ENPP2 (0.53) ALDH1A1ENPP2
Oxyquinoline SCHEMBL5166805 0.81 MMP2 (0.43) MMP2CHRM1TSHRCOMTADRA1A
Oxyquinoline SCHEMBL5166181 0.78 MMP2 (0.45) MMP2CHRM1TSHRCOMTADRA1A
Oxyquinoline SCHEMBL5168551 0.77 MMP2 (0.51) MMP2CHRM1TSHRCOMTADRA1A
Oxyquinoline SCHEMBL5164457 0.77 MMP2 (0.51) MMP2CHRM1TSHRCOMTADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1771182-A1 ANTI-PARASITIC USES OF BORINIC ACID COMPLEXES Anacor Pharmaceuticals, Inc. (US) 2007-04-11 EP disclosed
US-20060014723-A1 Anti-parasitic uses of borinic acid complexes ANACOR PHARMACEUTICALS, INC. 2006-01-19 US disclosed
WO-2005123095-A1 ANTI-PARASITIC USES OF BORINIC ACID COMPLEXES ANACOR PHARMACEUTICALS, INC. (US) 2005-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014723-A1 Anti-parasitic uses of borinic acid complexes BPGM, HRH1, HRH3 MMP2 1009/4885CHRM1 2017/4885TSHR 3633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.